Multiple Sclerosis Information
Main Page  »  Therapies  »  Betaseron
View Article  Prednisone & Acetaminophen both for Flu Like Symptoms
Prednisone or acetaminophen may significantly control flulike symptoms (FLSs) in patients with relapsing multiple sclerosis (MS) who are treated with interferon (IFN) beta-1a, according to a study presented here at the   more »
View Article  Betaseron: New Tritation Packs
Bayer will launch a titration pack for patients with multiple sclerosis (MS) that is specially designed to make it easier for them to start Betaferon® / Betaseron (interferon beta-1b) therapy. From now on, the titration pack will be available in   more »
View Article  Interferon beta-1a (Betaseron & Rebif) vs. Alemtuzumab
In this phase 2, randomized, blinded trial involving previously untreated, early, relapsing-remitting multiple sclerosis, we assigned 334 patients with scores of 3.0 or less on the Expanded Disability Status Scale and a disease duration of 3 years or less to receive   more »
View Article  BETASERON® now offers the thinnest needle
Bayer HealthCare Pharmaceuticals Inc. is proud to announce that BETASERON (interferon beta-1b) is now available with a new 30-gauge needle, which is the thinnest needle in MS therapy. The new   more »
View Article  MS Therapies - Betaseron
Interferon beta-1b belongs to a class of medications known as immunomodulators. It is used to reduce the frequency of exacerbations (worsening of symptoms) in people suffering with relapsing-remitting multiple sclerosis. Multiple sclerosis (MS) is caused by   more »
View Article  Rash from interferon beta 1-a (Rebif or Betaseron)
We describe a 41-year-old woman with multiple sclerosis, who presented with redness of the skin; several discoloured areas; along with inflammatory small,   more »
View Article  Predictive markers for response to interferon therapy in patients with multiple sclerosis.
Prolonged therapy with interferon beta (IFNbeta) often leads to the development of anti-IFNbeta binding antibodies (BAbs). A subset of the BAbs is of a neutralizing nature (neutralizing antibodies, NAbs) and   more »
View Article  Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
Biogen Idec Inc. and PDL BioPharma, Inc. (PDL) announced that Phase 2 data demonstrated a significant reduction in new or enlarged gadolinium- enhancing lesions when daclizumab   more »
View Article  A Controlled Trial of Tysabri (Natalizumab) for Relapsing Multiple Sclerosis
The glycoprotein integrin is expressed on the surface of these cells and plays a critical part in their adhesion to the vascular endothelium and migration into the parenchyma. Tysabri (Natalizumab) is an integrin antagonist that reduced the development of brain lesions in   more »
View Article  FDA Approves Betaseron for Use After the First Event Suggestive of Multiple Sclerosis
The two-year study showed that treatment with Betaseron delayed the time to a second clinical event by one year compared to placebo. (1) BENEFIT is the only trial to demonstrate the   more »
View Article  Interferon Beta-1b Delays Development of MS

BENEFIT Study Shows Interferon Beta-1b Delays Development of MS in Patients with First Clinical Signs of Disease

 

BASEL, SWITZERLAND -- October 14, 2005 –

 

Interferon beta-1b 250 mcg* ...   more »

View Article  Early Treatment With Betaseron Significantly Delayed the Time to a Second Clinical Event
Using interferon beta-1b (Betaseron) therapy in patients with the first clinical symptoms of MS (MS) significantly postpones the development of   more »
View Article  Patients Treated With Betaseron(R) After First MS Attack

Landmark Study in The Lancet:

 

Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression

 

 WAYNE, N.J.,

 ...   more »

View Article  New natural history of interferon-beta-treated RRMS

New natural history of interferon-beta-treated relapsing multiple sclerosis.

Department of Neurological and Psychiatric Sciences,

University of Bari,

Bari, Italy.

OBJECTIVE:

 

To investigate the impact ...   more »